奥拉西坦治疗血管性痴呆的Meta分析Meta analysis of oxiracetam in the treatment of vascular dementia
曲世为,曲连悦,陈希,张伟,李霄理,冯婉玉
QU Shi-wei,QU Lian-yue,CHEN Xi,ZHANG Wei,LI Xiao-li,FENG Wan-yu(The First Hospital
摘要(Abstract)：
目的评价奥拉西坦治疗血管性痴呆的疗效和安全性。方法检索中国知识资源总库、万方数据库、中国科技期刊全文数据库,手工检索其他的相关文件,对纳入研究进行方法学质量评价,并采用Cochrane协作网提供的Rev Man5.0.0软件进行Meta分析。结果共纳入8个研究。Meta分析结果显示,奥拉西坦在改善患者简易精神状态检查量表(mini-mental state examination,MMSE)、Barthel和神经功能缺损量表(national institutes of health strolke scale,NIHSS)评分值方面要优于安慰剂(P<0.05),但在以吡拉西坦为对照的研究中,患者MMSE、Blessed评分值没有统计学意义(P>0.05),提示奥拉西坦的疗效与吡拉西坦相似。在不良反应发生概率方面,实验组与对照组相似,并无统计学差异(P>0.05)。结论奥拉西坦治疗血管性痴呆的疗效肯定,不良反应轻微,与吡拉西坦相似。但由于纳入研究质量较低,上述结论需谨慎对待,期待日后有高质量,长期,大样本的试验进一步验证上述结论。
Objective Review the effect and safety of oxiracetam for vascular dementia.Methods CBM、Wanfang Database、CNKI were searched and hand-searched of other relevant researches.Randomized controlled trial(RCT)that included were evaluated and analyzed by the software of Rev Man 5.0.0.Results There were 8 researches included.The results of Meta-analysis showed that oxiracetam was more effective than the placebo about MMSE,Barthel and NIHSS(P>0.05),but MMSE,Blessed was not statistically significant(P>0.05)in the controlled study of piracetam in patients,which suggested oxiracetam has the similar efficacy with piracetam.In terms of the probability of adverse reactions,there was no statistically significant difference between the two groups(P>0.05).Conclusions Oxiracetam has the positive effect of VD and adverse reactions were mild but similar to piracetam.However,due to low quality of included researches,these conclusions should be cautious and the look-term tests with high-quality and large samples should be carried out in the future in order to further verify the above conclusions.
关键词(KeyWords)：
奥拉西坦;Meta分析;疗效;安全性;血管性痴呆
oxiracetam;Meta-analysis;effect;safety;vascular dementia
基金项目(Foundation):
作者(Author):
曲世为,曲连悦,陈希,张伟,李霄理,冯婉玉
QU Shi-wei,QU Lian-yue,CHEN Xi,ZHANG Wei,LI Xiao-li,FENG Wan-yu(The First Hospital
DOI: 10.14066/j.cnki.cn21-1349/r.2010.12.002
参考文献(References)：
- [1]王新德.老年人痴呆[M].北京:人民卫生出版社,1990:160-173.
- [2]STRUB R.Vascular dementia[J].South Med,2003,96(4):3632-366.
- [3]JUNI P,ALTMAND G,EGER M.Assessing the qualityof controlled trails[J].BMJ,2001,323:42-46.
- [4]HIGGINS J P T,THOMPSON S G.Quantify heteroge-neity in a meta-analysis[J].Stat Med,2002,21(11):1539-1558.
- [5]海力比努尔,王荫华,赵发国.奥拉西坦与吡拉西坦治疗血管性痴呆的随机双盲对照研究[J].中国新药与临床杂志,2003,22(11):647-650.
- [6]赵桂萍,王荫华,赵玉宾,等.国产奥拉西坦治疗痴呆的临床评价[J].中国临床药理学杂志,1997,13(1):17-21.
- [7]李梅,尹帅颖,卜淑芳,等.奥拉西坦胶囊治疗血管性痴呆疗效观察[J].中国实用神经疾病杂志2010,13(7):87-88.
- [8]张益.奥拉西坦治疗血管性痴呆34例[J].中国药业,2009,18(11):64.
- [9]潘华舫.奥拉西坦治疗血管性痴呆的疗效观察[J].现代中西医结合杂志,2006,15(15):2053-5054.
- [10]王爱群.奥拉西坦治疗血管性痴呆的临床观察[J].中国现代药物应用,2010,4(3):123-124.
- [11]段红莉,苗树均,张秀敏.奥拉西坦治疗血管性痴呆的临床疗效观察[J].临床荟萃,2008,23(6):437-438.
- [12]史红逸.奥拉西坦治疗血管性痴呆疗效分析[J].中国误诊学杂志,2010,10(12):2863-2864.